0.100
0.00 (0.00%)
| Penutupan Terdahulu | 0.100 |
| Buka | 0.190 |
| Jumlah Dagangan | 31,864 |
| Julat 52 Minggu |
| Margin Keuntungan | -38.34% |
| Margin Operasi (TTM) | -64.69% |
| EPS Cair (TTM) | -1.30 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 34.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 13.20% |
| Nisbah Semasa (MRQ) | 1.88 |
| Aliran Tunai Operasi (OCF TTM) | -18.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.96 M |
| Pulangan Atas Aset (ROA TTM) | -40.24% |
| Pulangan Atas Ekuiti (ROE TTM) | -149.41% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | Biofrontera Inc. Warrants | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | NA |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | -0.67 |
|
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |